卵巢癌靶向治疗药物偶联靶点的研究进展

发布时间：2018-06-28 21:33

  本文选题：卵巢癌 + 靶向治疗　； 参考：《重庆医学》2016年30期

【摘要】：正女性生殖器官恶性肿瘤中,卵巢癌病死率位居首位[1],且发病率逐年增加。靶向治疗指针对已明确的致癌位点(蛋白分子或基因片段)设计相应治疗药物,药物在体内特异性结合致癌位点并发生作用,使癌细胞特异性死亡。这就要求靶向治疗药物同时具有杀伤作用和靶向作用,卵巢癌靶向治疗中多种药物对癌细胞的杀伤作用显著,但因其靶向作用差导致的对正常
[Abstract]:Among the malignant tumors of female reproductive organs, the mortality of ovarian cancer is the highest [1], and the incidence of ovarian cancer is increasing year by year. Targeted therapy pointers are designed for specific carcinogenic sites (protein molecules or gene fragments), which specifically bind to carcinogenic sites in vivo and act on them, resulting in the specific death of cancer cells. This requires that targeted therapy drugs have both killing and targeting effects. In ovarian cancer targeted therapy, many drugs have significant killing effects on cancer cells, but due to their poor targeting effect, many drugs have a significant killing effect on cancer cells.
【作者单位】： 华北理工大学研究生学院;河北省唐山市工人医院妇产科;
【分类号】：R737.31
，

本文编号：2079425